Rochester, Minnesota 55905


To assess if infliximab drug levels in subjects with Ulcerative Colitis predict risk of colectomy rate. Additionally, the investigators will estimate an optimal day 4 infliximab level based on the study results.

Study summary:

Infliximab is approved for induction and maintenance of clinical remission and mucosal healing in patients with moderate to severe active ulcerative colitis, in those who have an inadequate response to conventional therapy such as IV steroids. It is typically dosed at 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter. The alternative to rescue medical therapy with infliximab is proctocolectomy with ileal pouch anastomosis, which carries risks including pouchitis, fecal incontinence, pouch failure requiring further surgical procedures and female infertility, or proctocolectomy with permanent end-ileostomy, which many patients wish to avoid. The induction regimen of 3 doses of Infliximab followed by a maintenance dose every 8 weeks is used to achieve response in hopes of avoiding colectomy. Unfortunately, a large proportion of patients are unable to achieve or sustain a clinical response over time and end up getting a colectomy. Potential implicated pathways in non-responders include fecal wasting of infliximab and factors that accelerate drug clearance such as a large TNF (tumor necrosis factor) or CRP (C reactive protein) burden, anti-infliximab antibodies (ATI), low serum albumin, male sex and larger body size. Patients with severe ulcerative colitis who fail corticosteroids and standard dosing with infliximab usually proceed to proctocolectomy. Optimizing early infliximab blood levels in patients with moderate-severe ulcerative colitis by administering the second dose of infliximab before week 2 could improve the efficacy and further reduce the need for colectomy. However, there is a paucity in the literature as this is a relatively new school of thought. Our study will address this deficit by evaluating the relationship between early drug levels of infliximab in ulcerative colitis and colectomy rates at one and three months.


Inclusion Criteria 1. Adults, ages 18-65 years 2. Hospitalized, with a moderate -severe flare. Based on the Mayo Scoring System for Assessment of Ulcerative Colitis Activity (Mayo score of equal or greater than 6) 3. Treatment naïve to anti TNF agents 4. Initiation of infliximab, with or without immunomodulator such as azathioprine 5. Ongoing use of immunomodulators such as azathioprine or 6MP is acceptable. Their initiation or continuation remains at the discretion of the treating physician Exclusion Criteria 1. Ongoing or prior treatment with Infliximab or other anti TNF agents 2. Ongoing or recent (with in 1 month) administration of rescue cyclosporine 3. Fulminant colitis requiring emergent surgery or toxic megacolon 4. Pregnancy 5. Infectious colitis, for example Clostridium difficile or CMV (cytomegalovirus) colitis 6. Active infection or abscess 7. Untreated latent or active tuberculosis (TB). Those with latent TB who are currently undergoing treatment can be included. Please refer to appendix 1 for more information on specific inclusion and exclusion criteria related to TB testing. Refer to 1.4.2 of appendix 1 for TB screening questions 8. Active malignancy 9. Active or history of Congestive Heart failure (CHF) or those who have received treatment for CHF 10. Active or history of Multiple Sclerosis (MS), or those who have received treatment for MS 11. Prisoners, institutionalized individuals, and individuals who are not capable of giving informed consent 12. Judgement of investigator



Primary Contact:

Principal Investigator
Darrell S Pardi, MD
Mayo Clinic

Darrell S Pardi, MD
Phone: 507-284-2407

Backup Contact:

Patricia Kammer, CCRP
Phone: 507-538-1827

Location Contact:

Rochester, Minnesota 55905
United States

Patty Kammer

Site Status: Recruiting

Data Source:

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.